<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01357135</url>
  </required_header>
  <id_info>
    <org_study_id>0431-201</org_study_id>
    <nct_id>NCT01357135</nct_id>
  </id_info>
  <brief_title>An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)</brief_title>
  <official_title>Observational Study of the Treatment and Follow-up of Patients With Type II Diabetes Receiving Bitherapy With or Without Sitagliptin (Januvia®/Xelevia®).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study to compare the effectiveness of dual therapy of Type II
      diabetes mellitus with metformin + sitagliptin versus metformin + a sulfonylurea in routine
      clinical practice in France.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2009</start_date>
  <completion_date type="Actual">August 31, 2013</completion_date>
  <primary_completion_date type="Actual">August 31, 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Median Duration (in Months) of Initial Dual Therapy</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The treatment maintenance duration corresponds to the treatment maintenance and persistence duration for dual therapy combining the same agents. Withdrawal of an agent, replacement of one agent by another or addition of a third agent is perceived as a change in treatment and, hence, the end of the treatment maintenance duration for dual therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Strict Changes in Initial Dual Therapy</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Strict changes in dual therapy were defined as withdrawal of an agent, replacement of one agent by another, or the addition of a third agent. Changes in dose level were not considered strict changes.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">3453</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Metformin + Sitagliptin</arm_group_label>
    <description>Participants taking metformin + sitagliptin (Januvia®/Xelevia®) as prescribed in routine clinical practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Sulfonylurea</arm_group_label>
    <description>Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin +/- Other Antihyperglycemic Medication</arm_group_label>
    <description>Participants taking sitagliptin +/- other antihyperglycemic medication (other than metformin) as prescribed in routine clinical practice. These other antihyperglycemic medications could include: insulin, glinides, sulfonylurea, glitazone, an alpha-glucosidase inhibitor, or combinations thereof.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Metformin + Sitagliptin</arm_group_label>
    <arm_group_label>Metformin + Sulfonylurea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <arm_group_label>Metformin + Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfonylurea</intervention_name>
    <arm_group_label>Metformin + Sulfonylurea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antihyperglycemic Medication</intervention_name>
    <arm_group_label>Sitagliptin +/- Other Antihyperglycemic Medication</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with type II diabetes mellitus receiving a de novo prescription (for the first
        time or within less than 8 weeks) for dual therapy with or without Januvia®/Xelevia® or any
        other treatment regimen including Januvia®/Xelevia® by general practitioners in private
        practice under real life conditions without any additional treatment or monitoring
        procedures.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes participants

          -  De novo treatment (first prescription or dated within the past 8 weeks) with:

          -  Metformin + sitagliptin dual therapy,

          -  Metformin + sulfonylurea dual therapy,

          -  Sitagliptin as part of another treatment regimen

          -  Participants also eligible for treatment with sitagliptin (Januvia®/Xelevia®) or a
             sulfonylurea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <results_reference>
    <citation>Valensi P, de Pouvourville G, Benard N, Chanut-Vogel C, Kempf C, Eymard E, Moisan C, Dallongeville J. Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study. Diabetes Metab. 2015 Jun;41(3):231-8. doi: 10.1016/j.diabet.2015.03.007. Epub 2015 May 12.</citation>
    <PMID>25976701</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2011</study_first_posted>
  <results_first_submitted>November 14, 2014</results_first_submitted>
  <results_first_submitted_qc>December 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2014</results_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=0431-201&amp;kw=0431-201&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was an observational, non-randomized, prospective, longitudinal study of participants with Type 2 diabetes mellitus treated in routine clinical practice by 1,569 primary care practitioners in metropolitan France. Study participants were enrolled from July 29, 2009 to December 31, 2010. The end of study follow-up was August 31, 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin + Sitagliptin</title>
          <description>Participants taking metformin + sitagliptin (Januvia®/Xelevia®) as prescribed in routine clinical practice.</description>
        </group>
        <group group_id="P2">
          <title>Metformin + Sulfonylurea</title>
          <description>Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride.</description>
        </group>
        <group group_id="P3">
          <title>Sitagliptin +/- Other Antihyperglycemic Medication</title>
          <description>Participants taking sitagliptin +/- other antihyperglycemic medications (other than metformin) as prescribed in routine clinical practice. These other antihyperglycemic medications could include: insulin, glinides, sulfonylurea, glitazone, an alpha-glucosidase inhibitor, or combinations thereof.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1874"/>
                <participants group_id="P2" count="733"/>
                <participants group_id="P3" count="846"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1276"/>
                <participants group_id="P2" count="510"/>
                <participants group_id="P3" count="583"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="598"/>
                <participants group_id="P2" count="223"/>
                <participants group_id="P3" count="263"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline gender data is missing for 8 participants in the Metformin + Sitagliptin group.</population>
      <group_list>
        <group group_id="B1">
          <title>Metformin + Sitagliptin</title>
          <description>Participants taking metformin + sitagliptin (Januvia®/Xelevia®) as prescribed in routine clinical practice.</description>
        </group>
        <group group_id="B2">
          <title>Metformin + Sulfonylurea</title>
          <description>Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride.</description>
        </group>
        <group group_id="B3">
          <title>Sitagliptin +/- Other Antihyperglycemic Medication</title>
          <description>Participants taking sitagliptin +/- other antihyperglycemic medications (other than metformin) as prescribed in routine clinical practice. These other antihyperglycemic medications could include: insulin, glinides, sulfonylurea, glitazone, an alpha-glucosidase inhibitor, or combinations thereof.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1874"/>
            <count group_id="B2" value="733"/>
            <count group_id="B3" value="846"/>
            <count group_id="B4" value="3453"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="10.8"/>
                    <measurement group_id="B2" value="64.2" spread="11.5"/>
                    <measurement group_id="B3" value="65.5" spread="11.3"/>
                    <measurement group_id="B4" value="63.5" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="758"/>
                    <measurement group_id="B2" value="311"/>
                    <measurement group_id="B3" value="372"/>
                    <measurement group_id="B4" value="1441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1108"/>
                    <measurement group_id="B2" value="422"/>
                    <measurement group_id="B3" value="474"/>
                    <measurement group_id="B4" value="2004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Duration (in Months) of Initial Dual Therapy</title>
        <description>The treatment maintenance duration corresponds to the treatment maintenance and persistence duration for dual therapy combining the same agents. Withdrawal of an agent, replacement of one agent by another or addition of a third agent is perceived as a change in treatment and, hence, the end of the treatment maintenance duration for dual therapy.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>All eligible participants receiving dual therapy with metformin + sitagliptin or metformin + sulfonylurea.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin + Sitagliptin</title>
            <description>Participants taking metformin + sitagliptin as prescribed in routine clinical practice.</description>
          </group>
          <group group_id="O2">
            <title>Metformin + Sulfonylurea</title>
            <description>Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Duration (in Months) of Initial Dual Therapy</title>
          <description>The treatment maintenance duration corresponds to the treatment maintenance and persistence duration for dual therapy combining the same agents. Withdrawal of an agent, replacement of one agent by another or addition of a third agent is perceived as a change in treatment and, hence, the end of the treatment maintenance duration for dual therapy.</description>
          <population>All eligible participants receiving dual therapy with metformin + sitagliptin or metformin + sulfonylurea.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1874"/>
                <count group_id="O2" value="733"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" lower_limit="41.4">There were insufficient number of participants with events to estimate an upper confidence limit.</measurement>
                    <measurement group_id="O2" value="20.2" lower_limit="17.0" upper_limit="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Strict Changes in Initial Dual Therapy</title>
        <description>Strict changes in dual therapy were defined as withdrawal of an agent, replacement of one agent by another, or the addition of a third agent. Changes in dose level were not considered strict changes.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>All eligible participants receiving dual therapy metformin + sitagliptin or metformin + sulfonylurea.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin + Sitagliptin</title>
            <description>Participants taking metformin + sitagliptin as prescribed in routine clinical practice.</description>
          </group>
          <group group_id="O2">
            <title>Metformin + Sulfonylurea</title>
            <description>Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Strict Changes in Initial Dual Therapy</title>
          <description>Strict changes in dual therapy were defined as withdrawal of an agent, replacement of one agent by another, or the addition of a third agent. Changes in dose level were not considered strict changes.</description>
          <population>All eligible participants receiving dual therapy metformin + sitagliptin or metformin + sulfonylurea.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1874"/>
                <count group_id="O2" value="733"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1"/>
                    <measurement group_id="O2" value="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 3 years</time_frame>
      <desc>Population of participants receiving treatment with metformin + sitagliptin or metformin + sulfonylurea or sitagliptin +/- other antihyperglycemic medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Metformin + Sitagliptin</title>
          <description>Participants taking metformin + sitagliptin as prescribed in routine clinical practice.</description>
        </group>
        <group group_id="E2">
          <title>Metformin + Sulfonylurea</title>
          <description>Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride.</description>
        </group>
        <group group_id="E3">
          <title>Sitagliptin +/- Other Antihyperglycemic Medication</title>
          <description>Participants taking sitagliptin +/- other antihyperglycemic medications (other than metformin) as prescribed in routine clinical practice. These other antihyperglycemic medications could include: insulin, glinides, sulfonylurea, glitazone, an alpha-glucosidase inhibitor, or combinations thereof.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="1874"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="733"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Gastritis Erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="1874"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="733"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Heptatomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Viral pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaesthetic complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Dural tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Blood culture positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Cardiac stress test</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Bone neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Colon cancer Stage 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of ampulla of vater</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Malignant peritoneal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Metatases to bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Metatases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Pleural mesothelioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Prostate cancer Stage III</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="733"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired diaphragmatic eventration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Arthrodesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Diverticulectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Gastrectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="733"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="846"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators cannot disclose any results without sponsor’s agreement, only on request of French Health Authorities as per French law.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The adverse events in this study were not systematically collected or assessed and therefore no direct comparison can be made between adverse events in the 3 study groups/arms.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

